Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focused on creating value for people living with severe diseases in immunology and neurology now and into the future.
We work with stakeholders to address the unmet needs of patients and caregivers, helping them to achieve their goals and to live the lives they want. UCB is on a journey to become the patient-preferred biopharma leader by delivering medicines and solutions that improve lives, while creating value for society. Our commitment to value is a promise to bring together the talent, expertise, tools and scientific know-how required to serve patients in need.
Twitter Feed
-
Worldwide, #osteoporosis is estimated to cause 9 million #fractures annually. In the EU alone, the annual number is predicted to rise by 28% in 2025. We thank #ECTS2021 for providing the opportunity to share scientific advancements that can improve patien
— UCB News (@ucb_news) 08.05.2021 -
UCB is committed to supporting the axSpA community through purposeful partnerships that empower patients, raise awareness, and improve axSpA patient care and outcomes. Find out more https://t.co/U3D4cN6bVh
— UCB News (@ucb_news) 07.05.2021 -
Do you want to hear from @CaroWozniacki and a team of experts about how to best manage your chronic inflammatory disease? Register to join the #AdvantageHers #EURoadshow between May 18 – 21 in your language here!
— UCB News (@ucb_news) 07.05.2021
Instagram Feed
At UCB, we take our responsibility
to the planet very seriously.
UCB Ventures, our strategic corporate venture fund established in 2017
